Response to "The Afatinib Response to EGFR E709G-mutated Lung Cancer"

Response to Letter to the Editor on "The Afatinib Response to EGFR E709G-mutated Lung Cancer"
Tamio Okimoto, Tasuku Kato, Kojiro Hata
Internal Medicine15 Jul 2026Peer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
Venetoclax plus hypomethylating agent improves response rates but not survival in TP53-mutated myelodysplastic syndromes.
Michael Canonico, Parth Patel, Najla H Al Ali +15
Blood neoplasia21 Sep 2026Peer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
Integrated stress response activation in combination PG3 and cisplatin-treated TP53-mutated head and neck squamous carcinoma cells induces potent apoptotic response
X. Tian, P. Srinivasan, W. S. El-Deiry
bioRxiv22 Sep 2026PreprintCC BY-NC-NDFull textOncologybioRxiv
Genetic dissection of DNA damage response pathways reveals divergent modulation of PD-1 blockade response in colorectal cancer
F. Fece de la Cruz, E. Wong, H. Barnes +8
bioRxiv3 Oct 2026PreprintAll rights reservedFull textOncologybioRxiv
Pan-Cancer Gene Expression Predicts Per-Cancer Radiation Therapy Response
Harry Glickman, Shirin A. Enger
Advances in radiation oncology27 Jul 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeX

@article{isaac2026response,
  title = {{Response to "The Afatinib Response to EGFR E709G-mutated Lung Cancer"}},
  author = {Sangeetha Isaac and Misbah Qadir},
  journal = {Internal Medicine},
  year = {2026},
  month = jul,
  doi = {10.2169/internalmedicine.5658-25},
  url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/14/65_5658-25/_article},
  note = {CC BY-NC-ND},
}

RIS

TY  - JOUR
TI  - Response to "The Afatinib Response to EGFR E709G-mutated Lung Cancer"
AU  - Sangeetha Isaac
AU  - Misbah Qadir
PY  - 2026
DA  - 2026/07/15
JO  - Internal Medicine
DO  - 10.2169/internalmedicine.5658-25
UR  - https://www.jstage.jst.go.jp/article/internalmedicine/65/14/65_5658-25/_article
SN  - 1349-7235
SN  - 0918-2918
ER  -

Related

Cite